DCPH News and Press, Deciphera Pharmaceuticals Inc. From 10/04/19

The following slide deck was published by Deciphera Pharmaceuticals, Inc. in conjunction with this Read more ...

Accomplished CMO Brings Deep Clinical Drug Development Expertise from Leading Biotech and Pharma Companies Deciphera Pharmaceuticals, Inc . (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that it has appoint...

Deciphera Pharmaceuticals, Inc . (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced the late-breaking presentation of results from the INVICTUS pivotal Phase 3 clinical study of ripretinib in patients with advanced ga...

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 2019 Cantor Global Healthcare Conference on W...

Noteworthy events during the week of September 22 - 28 for healthcare investors. More news on: UroGen Pharma Ltd., Medtronic plc, ENDRA Life Sciences Inc., Healthcare stocks news, , Read more ...

Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that data from the Company’s INVICTUS pivotal Phase 3 study of ripretinib in patients with fourth-line and fourth-lin...

Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that the underwriters of its previously announced public offering of common stock have exercised their option to purchase an...

Deciphera Pharmaceuticals ( DCPH ) announced that it had achieved positive results in a phase 3 study , using its drug ripretinib to treat patients with fourth-line and fifth-line plus gastrointestinal stromal tumors ((GIST)). With these latest results, the biotech holds the potential to ...

Shares of Deciphera Pharmaceuticals (DCPH) have risen by just 1% since my September 2018 article suggested initiating a pilot position in the near term and accumulating weakness. To be fair, I had thought ESMO data for DCC-2618 would boost shares and instead they lost nearly half their value...

Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the closing of its previously announced registered underwritten public offering. 10,810,810 shares of the Company’s c...